ArticleTobacco control2026
Changes in combustible cigarette and electronic nicotine delivery system use among people with and without schizophrenia spectrum disorders in the USA (2016-2023).
Article in Tobacco control, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundChanges in population estimates for electronic nicotine delivery systems (ENDS) have not been investigated in people with schizophrenia-spectrum disorders (SSDs). We assess the prevalence of daily use of ENDS, cigarettes or dual use, and changes in daily use among individuals with SSDs compared with the general population.
methodsRespondents are from the Population Assessment of Tobacco and Health Study, 2016-2023 (age 18+ years) reporting (yes/no) daily combustible cigarette, daily ENDS or daily dual use at each wave (n=33 689 (517 SSD) in 2016-2017). Weighted generalised linear regression models were used to assess changes in odds of use for each product by self-reported SSD diagnosis.
resultsIn 2023, people with SSDs reported significantly higher rates of daily cigarette smoking (31.5%, 95% CI 28.6% to 34.4%), ENDS use (6.6%, 95% CI 5.2% to 8.0%) and dual use (1.8%, 95% CI 0.9% to 2.7%), relative to the general population (cigarettes: 10.0% (95% CI 9.7% to 10.2%); ENDS: 3.2% (95% CI 3.1% to 3.4%); dual use: 0.4% (95% CI 0.3% to 0.4%)). From 2016-2023, odds of daily cigarette smoking decreased comparably in people with and without SSDs, but remained significantly higher among people with SSDs over time. Additionally, there was an increase in the odds of ENDS use among people with (OR 1.26, 95% CI 1.11 to 1.43) and without SSDs (OR 1.07, 95% CI 1.05 to 1.10), that was comparable after adjusting for age. Odds of all three daily nicotine use patterns, as well as ENDS and cigarette dependence, were higher in people with SSDs over time. CONCLUSIONS AND RELEVANCE: Despite comparable declines in daily smoking and increases in daily vaping, rates of smoking, ENDS use and dual use were persistently higher among people with SSDs, demonstrating continued nicotine/tobacco health disparities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.